Allyx Therapeutics aims to deliver a novel approach

to preserve and protect synapses

for people living with neurodegenerative diseases

Latest News from Allyx

March 5, 2024

Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance

October 30, 2023

Allyx Therapeutics releases top-line Phase 1a data for ALX-001, demonstrating oral administration is safe and well-tolerated at all doses and achieves full brain receptor occupancy.

October 19, 2023

Allyx Therapeutics to Present Phase 1a Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer’s Disease Meeting